WIPO logo
Mobile | Deutsch | English | Español | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Recherche dans les collections de brevets nationales et internationales
World Intellectual Property Organization
Recherche
 
Options de navigation
 
Traduction
 
Options
 
Quoi de neuf
 
Connexion
 
Aide
 
maximize
Traduction automatique
1. (WO2002024172) COMPOSITION PHARMACEUTIQUE SEMI-SOLIDE D'ISOTRETINOINE
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique
WHAT WE CLAIMS IS :

1. An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.

2. The pharmaceutical composition of claim 1 , which contains at least one hydrophilic excipient(s) with a HLB value of at least 10, preferably at least 12, most preferably at least 13, selected from the group consisting of glyceroyl macrogolglycerides, polyethyleneglycol derivatives, and mixtures thereof.
3. The pharmaceutical composition of claim 2, which contains from 20 to 80% by weight of hydrophilic excipient with a HLB value of at least 10 selected from the group consisting of glyceroyl macrogolglycerides, polyethyleneglycol derivatives, and mixtures thereof .
4. The pharmaceutical composition of claim 1 , which contains an oily vehicle selected from the group consisting of vegetable oils, medium chain triglycerides, fatty acid esters, amphiphilic oil, glycerol oleate derivative, and mixtures thereof.
5. The pharmaceutical composition of claim 1 , which contains from 5 to

70% by weight of an oily vehicle selected from the group consisting of vegetable oils, medium chain triglycerides, fatty acid esters, amphiphilic oil, glycerol oleate derivative, and mixtures thereof.
6. The pharmaceutical composition of claim 1 , which contains at least one surfactant.
7. The pharmaceutical composition of claim 1 , which contains at least one surfactant selected from the group consisting of sorbitan fatty acid esters, polysorbate derivatives, polyoxyethylene sorbitan fatty acid esters, sodium laurylsulphate, derivatives of lecithine, propylene glycol esters, fatty acid esters of propylene glycol, fatty acid esters of glycerol, polyethylene glycol, and mixtures thereof.

8. The pharmaceutical composition of claim 1 , which contains from 1 to 10% by weight of at least one surfactant.
9. The pharmaceutical formulation of claim 1 , which contains at least one disintegrant.
10. The pharmaceutical composition of claim 1 , which comprises at least one disintegrant selected from the group consisting of povidone derivative, sodium croscarmellose and mixtures thereof.
11. A pharmaceutical acceptable capsule containing at least one semi- solid composition according to anyone of the preceding claims.
12. The capsule of claim 11 , in which the capsule is selected from the group consisting of hard gelatine capsules, soft gelatine capsules, hypromellose capsules, starch capsules.